Assorted news from last week: A primer on where the Centers for Medicare and Medicaid Services see Medicaid and the Children’s Health Insurance Program (CHIP)
Assorted news from last week: Provocative article written by pediatric cancer advocates, including several CAC2 members — innovation can be crippled by commercialization — meaning
Assorted news from last week: Save the Date: CureFest 2022 will be held Sep. 24 and 25 in Washington, DC. Second Paediatric Strategy Forum for
Assorted news from last week: Save the Date: CureFest 2022 will be held Sep. 24 and 25 in Washington, DC. The Children’s Brain Tumor Network
Assorted news from last week: Save the Date: CureFest 2022 will be held Sep. 24 and 25 in Washington, DC. The World Health Organization (WHO)
Assorted news from last week: CAC2 Ethics Think Tank presented a paper entitled Cultivating Ethically Sustainable Relationships with Stakeholders When Non-Profits Fund Pediatric Cancer Clinical
Assorted news from last week: CAC2 Ethics Think Tank will present a paper entitled Cultivating Ethically Sustainable Relationships with Stakeholders When Non-Profits Fund Pediatric Cancer
Assorted news from last week: The FDA has granted a rare pediatric disease designation (RPDD) to lutetium-177(177Lu)-omburtamab-DTPA for use as a potential therapeutic option in
Assorted news from last week: CAC2 Member Mary Beth Collins, highlights the importance of Childhood Cancer License Plates, how they amplify awareness efforts, the advocacy
By CAC2 Member Mary Beth Collins, PREP4Gold For the entire month of September the world hears a great deal from the childhood cancer community, feverishly
